>
Switch to:

Cullinan Oncology Earnings Yield (Joel Greenblatt) %

: 0.00% (As of Dec. 2019)
View and export this data going back to 2021. Start your Free Trial

Cullinan Oncology's Enterprise Value for the quarter that ended in Dec. 2019 was $0.00 Mil. Cullinan Oncology does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2019. Therefore, GuruFocus does not calculate Cullinan Oncology's Earnings Yield (Joel Greenblatt) at this moment.

The historical rank and industry rank for Cullinan Oncology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cullinan Oncology's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2019 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Cullinan Oncology Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Cullinan Oncology's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Oncology Annual Data
Trend Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) %
- - -

Cullinan Oncology Semi-Annual Data
Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) % - - -

Competitive Comparison

For the Biotechnology subindustry, Cullinan Oncology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cullinan Oncology Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, Cullinan Oncology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cullinan Oncology's Earnings Yield (Joel Greenblatt) % falls into.



Cullinan Oncology Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Cullinan Oncologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2019 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-22.27/0
= %



Cullinan Oncology  (NAS:CGEM) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Cullinan Oncology Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cullinan Oncology's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cullinan Oncology Business Description

Cullinan Oncology logo
Industry
Healthcare » Biotechnology NAICS : 541713 SIC : 2834
Comparable Companies
Traded in Other Exchanges
N/A
Address
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Cullinan Oncology Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)